Previous 10 | Next 10 |
Gainers: Ameri Holdings (NASDAQ: AMRH ) +152% . More news on: Ameri Holdings, Inc., Westwater Resources, Inc., Genius Brands International, Inc., Stocks on the move, , Read more ...
Nano cap Aileron Therapeutics ( ALRN +10.8% ) is up in early trade in reaction to positive preliminary data from a Phase 1b/2 clinical trial evaluating ALRN-6924 as an agent to protect patients from chemo-induced toxicity, also known as chemoprotection or myelopreservation. More news o...
Edwards Lifesciences (NYSE: EW ) -66% . More news on: Edwards Lifesciences Corporation, Iterum Therapeutics plc, Novus Therapeutics, Inc., Stocks on the move, , Read more ...
- - - Observed a protective effect against severe chemotherapy-induced anemia and thrombocytopenia across all dose levels - - - Management to host a conference call and webcast today at 8:30 a.m. EDT - - - WATERTOWN, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Aileron Therape...
These Penny Stocks Just Hit New 52-Week Highs. Are They Still A Buy? There’s no getting around the fact that penny stocks are high-risk equities. Just as quickly as they move up, they can come crashing down. In line with this, there’ve been plenty of higher-priced stocks that r...
WATERTOWN, Mass., May 27, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) announced today the expansion of one of the dose levels in the dose optimization part of its Phase 1b/2 clinical trial evaluating ALRN-6924 as an agent to protect patients with small cell lung cancer (SCLC...
Aileron Therapeutics (NASDAQ: ALRN ): Q1 GAAP EPS of -$0.24 misses by $0.04 . More news on: Aileron Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Enrollment completed in the dose optimization part of the ongoing Phase 1b/2 clinical trial of ALRN-6924 as a chemoprotection agent in cancer patients - - - Scheduled to report interim results from the dose optimization part of the Phase 1b/2 trial 2 nd Quarter 2020, and planning f...
Presentation of interim results from the dose-optimization part of the Phase 1b myelopreservation study - - - Final data readout from Phase 1b for both dose optimization and schedule optimization in Q4 2020 - - - Updated corporate presentation available on the Company’...
Aileron Therapeutics (NASDAQ: ALRN ): Q4 GAAP EPS of -$0.26 beats by $0.01 . More news on: Aileron Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Aileron Therapeutics Inc. Company Name:
ALRN Stock Symbol:
NASDAQ Market:
Aileron Therapeutics Inc. Website:
Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference PR Newswire AUSTIN, Texas , July 30, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first...
Aileron Therapeutics to be Included in the Russell Microcap® Index PR Newswire AUSTIN, Texas , July 1, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron" or the "Company") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of...
Announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients with positive trends observed in seven of the eight biomarkers evaluated Topline results from Cohort 2 evaluating high-dose LTI-03 (5 mg BID) expected in ...